Autonomic neuropathy in systemic sclerosis: a case report and evaluation of six patients

C Sonnex,* E Paice, and A G White

From the Department of Rheumatology, Whittington Hospital, Highgate Hill, London.

SUMMARY We describe a case of systemic sclerosis with sympathetic and parasympathetic neuropathy and detail autonomic testing in six further patients. Of these six patients, three showed early parasympathetic damage. None of the patients had evidence of peripheral neuropathy, and there was no correlation between the presence of autonomic dysfunction and the severity of Raynaud’s phenomenon.

Autonomic neuropathy has not previously been reported in systemic sclerosis to our knowledge. Autonomic neuropathy has been described in rheumatoid arthritis and systemic lupus erythematosus, and impotence was recently described in systemic sclerosis but without formal studies of autonomic function. Other neurological manifestations of systemic sclerosis have been described but are rare. A mild peripheral neuropathy has been reported. Subacute combined degeneration of the cord following vitamin B12 deficiency secondary to sclerodermatous involvement of the small intestine has also been recorded.

We describe a patient with systemic sclerosis and autonomic neuropathy and detail our investigation of the autonomic nervous system in six other patients with scleroderma and eight control patients.

Case report

A 50 year old Asian woman first presented in 1968 with dysphagia, depigmentation and tightness of the skin of the hands, and Raynaud’s phenomenon. Systemic sclerosis was diagnosed and progressed slowly over subsequent years. By 1983 she had developed acro-osteolysis, flexion contractures of the fingers of the left hand, and fibrosing alveolitis. In 1984 she presented with abdominal pain and diarrhoea.

Investigations were as follows: haemoglobin 12.0 g/dl (120 g/l); mean corpuscular volume 83 fl; erythrocyte sedimentation rate 35 mm/1st h (Westergren); serum vitamin B12 230 ng/l (normal range 160–960 ng/l); red blood cell folate 180 pg/l (normal range 160–640 pg/l); stool culture negative; urinary indicans normal; three day faecal fat excretion normal. A small bowel enema showed rapid transit of contrast without evidence of diverticula. Fibre optic sigmoidoscopy to 40 cm was normal. During the course of investigation she complained of fainting episodes. Marked postural hypotension was found, the blood pressure dropping from 125/70 mmHg lying to 95/— mmHg standing. We went on to test for autonomic neuropathy in greater detail as we considered this might possibly have contributed to the diarrhoea. Subsequent autonomic testing showed sympathetic and parasympathetic damage (see ‘Results’, Table 1, case 1).

Since autonomic dysfunction has not been previously described in systemic sclerosis we proceeded to test six other patients with scleroderma for evidence of sympathetic or parasympathetic damage.

Subjects and methods

Autonomic testing was performed on six patients with systemic sclerosis as defined by the American Rheumatism Association and on eight healthy control subjects attending our physiotherapy department with osteoarthritis or soft tissue lesions. All were normotensive, none were in cardiac failure, anaemic, or receiving medications which influence cardiac rhythm. None had evidence of conditions previously described as relating to autonomic dysfunction. The methods used were those described by Ewing and Clarke and Smith.
Table 1 Results of autonomic testing in seven patients with systemic sclerosis and eight controls

<table>
<thead>
<tr>
<th>Case No</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Duration of illness (years)</th>
<th>Raynaud's phenomenon</th>
<th>Dysphagia</th>
<th>Postural drop in systolic blood pressure (normal ≤10 mmHg)</th>
<th>Diastolic blood pressure increase on sustained hand grip (normal ≥16 mmHg)</th>
<th>R-R standing 30:15 (normal ≥1:04)</th>
<th>E:1 single breath</th>
<th>Valsalva ratio (normal = 1:21)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Systemic sclerosis group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>F</td>
<td>50</td>
<td>17</td>
<td>Mild</td>
<td>Mild</td>
<td>30**</td>
<td>15*</td>
<td>0.93**</td>
<td>1.05**</td>
<td>Unable</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>45</td>
<td>6</td>
<td>Moderate</td>
<td>Severe</td>
<td>5</td>
<td>14*</td>
<td>0.99**</td>
<td>1.15*</td>
<td>1.29</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>54</td>
<td>7</td>
<td>Moderate</td>
<td>Mild</td>
<td>0</td>
<td>16</td>
<td>1.12</td>
<td>1.40</td>
<td>1.46</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>41</td>
<td>2</td>
<td>Moderate</td>
<td>Nil</td>
<td>10</td>
<td>25</td>
<td>1.08</td>
<td>1.22</td>
<td>1.36</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>49</td>
<td>12</td>
<td>Mild</td>
<td>Nil</td>
<td>0</td>
<td>Unable</td>
<td>1.03*</td>
<td>1.06**</td>
<td>Unable</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>66</td>
<td>7</td>
<td>Moderate</td>
<td>Mild</td>
<td>10</td>
<td>12*</td>
<td>1.07</td>
<td>1.07**</td>
<td>1.14*</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>53</td>
<td>5</td>
<td>Mild</td>
<td>Nil</td>
<td>4</td>
<td>32</td>
<td>1.04</td>
<td>1.26</td>
<td>1.26</td>
</tr>
<tr>
<td><strong>Control group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>F</td>
<td>45</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>6</td>
<td>18</td>
<td>1.18</td>
<td>1.29</td>
<td>1.75</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>32</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>4</td>
<td>39</td>
<td>1.31</td>
<td>1.31</td>
<td>2.21</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>61</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>5</td>
<td>43</td>
<td>1.20</td>
<td>1.22</td>
<td>1.76</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>47</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>0</td>
<td>23</td>
<td>1.10</td>
<td>1.19</td>
<td>1.76</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>61</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>0</td>
<td>25</td>
<td>1.12</td>
<td>1.10</td>
<td>1.81</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>27</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>0</td>
<td>21</td>
<td>1.41</td>
<td>1.59</td>
<td>2.16</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>51</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>0</td>
<td>16</td>
<td>1.19</td>
<td>1.23</td>
<td>1.70</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>55</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>5</td>
<td>18</td>
<td>1.19</td>
<td>1.17</td>
<td>1.38</td>
</tr>
</tbody>
</table>

*Borderline; **abnormal; no asterix—normal result.
Cardiac parasympathetic integrity was initially assessed by measuring the heart rate response to standing by continuous electrocardiographic tracing. The shortest R-R interval at or around the 15th beat after standing is compared with the longest R-R interval at or around the 30th beat. The 30:15 ratio is calculated, a result greater than or equal to 1:04 being regarded as normal. Ratios between 1:01 and 1:03 are borderline and below or equal to 1:00 abnormal. In addition we performed two further tests of parasympathetic function. The heart rate response to the Valsalva manoeuvre was measured for 15 seconds during the manoeuvre and for one minute after. The test was repeated three times and the mean of the three Valsalva ratios calculated (ratio of the longest R-R interval after the manoeuvre to the shortest R-R interval during the manoeuvre). Values greater or equal to 1:21 are normal, 1:11 to 1:20 borderline, and below or equal to 1:10 abnormal. Measurement of the degree of sinus arrhythmia resulting from a single forced respiratory cycle provided the final test for parasympathetic damage. The shortest R-R interval during inspiration (I) and the longest during expiration (E) were measured and the E:I ratio calculated. The ratio was compared with the age related normal range.14

Sympathetic damage was initially assessed by measuring the postural fall in systolic blood pressure on standing from a lying position. The normal fall in systolic pressure is less or equal to 10 mmHg. An 11–29 mmHg drop is borderline and greater than or equal to 30 mmHg abnormal. Sympathetic damage was further assessed by measuring the rise in diastolic blood pressure on sustained hand grip. Maximum voluntary contraction was first determined with a hand grip dynamometer. Hand grip was then maintained at 30% of that maximum for as long as possible up to five minutes. Only one patient (case No 5) was unable to perform the test. The normal increase in diastolic blood pressure during this test is greater than or equal to 16 mmHg. An increase of 11–15 mmHg is borderline and less than or equal to 10 mmHg abnormal.

Evidence of peripheral neuropathy was assessed by measuring vibration threshold with a biothesiometer. The medial malleoli and great toes of both feet were tested and results compared with age related centile charts as devised by Bloom et al.15 In case 1 motor and sensory nerve conduction velocities were measured to confirm the result obtained by biothesiometer.

Results
The results of autonomic testing in seven patients with systemic sclerosis and eight controls are shown in Table 1. Case 1 showed both sympathetic and parasympathetic damage. Of the six further patients with systemic sclerosis examined, three showed early parasympathetic dysfunction as defined by Ewing and Clarke.13

Vibration sensation thresholds were normal in both systemic sclerosis and control groups. In addition, case 1 had normal sensory and motor nerve conduction velocities.

Our results were compared with previously recorded normal ranges.13 14 In addition we tested eight control patients ourselves, to ensure that our methodology was correct. All results of our control patients fell within the normal range.

Discussion
Autonomic neuropathy has not previously been reported in systemic sclerosis. It is not clear why such patients should develop autonomic dysfunction. Possibly it is caused by compression of nerve fibres by collagen as postulated in the aetiology of peripheral neuropathy in this condition.6 Damage to the vasa nervorum may also have a role.

Diarrhoea is well recognised in systemic sclerosis. This may be due to a combination of vascular obstruction, altered motility, impairment of intestinal lymphatics, and bacterial overgrowth16 though in some cases it remains unexplained. We found no evidence of bacterial overgrowth, hypomotility, or malabsorption in our case. Autonomic neuropathy is thought to cause diarrhoea in patients with diabetes mellitus, and autonomic neuropathy may have contributed to or caused diarrhoea in our patient.

Oesophageal dysfunction develops in approximately 90% of patients with systemic sclerosis and may be one of the earliest manifestations.17 This is thought to be secondary to smooth muscle involvement, though autonomic neuropathy has not been previously assessed. In our small group of patients there appeared to be no correlation between the degree of dysphagia and autonomic dysfunction.

Raynaud's phenomenon occurs in up to 90% of patients with systemic sclerosis and may predate skin manifestations of the disease. Excess sympathetic activity was initially considered to be the cause by Raynaud in 1862, but this has not been substantiated.18 Indeed in our patients there was no correlation between the severity of Raynaud's phenomenon and autonomic dysfunction.

Autonomic neuropathy in patients with rheumatoid arthritis is usually associated with peripheral neuropathy.1 2 Our study group had normal vibration thresholds as assessed by the biothesiometer.
which suggests normal sensory peripheral nerve function.

We thank Dr M L Snaith and Dr D A Isenberg, University College Hospital, London and Dr S Corcoran, Whittington Hospital, London for their assistance.

References

Autonomic neuropathy in systemic sclerosis: a case report and evaluation of six patients.
C Sonnex, E Paice and A G White

doi: 10.1136/ard.45.11.957